Study of GS-1427 in Participants With Moderately to Severely Active Ulcerative Colitis
← catalyst calendarSponsored by Gilead Sciences (industry) · GILD — their whole pipeline →.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
228estimated
Sites
181
Countries
Australia, Austria, Belgium +19
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-03-27 | actual | When the study began enrolling |
| Primary completion | 2026-03-04 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Apr 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2024-03-04 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-09 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Ulcerative Colitis
Interventions
- Drug: emvistegrast — also filed as GS-1427
- Drug: Placebo-to-match emvistegrast
Primary outcome
what the primary-completion date above is the date OFProportion of Participants Achieving Clinical Response at Week 12
measured Week 12
Permalink · GILD's whole pipeline · Catalyst calendar · Every registered study · What changed